HK Stock MarketDetailed Quotes

01558 HEC CJ PHARM

Watchlist
  • 10.880
  • +0.060+0.55%
Market Closed Mar 28 16:08 CST
9.57BMarket Cap4.35P/E (TTM)

About HEC CJ PHARM Company

Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company” or “Dongyangguang Changjiang Pharmaceutical”, together with its subsidiaries collectively referred to as the “Group”) is a pharmaceutical enterprise focusing on the production, sales and development of pharmaceutical products in the fields of anti-infective, endocrine and metabolic treatments. It is a domestic formulation platform under the Dongyangguang Group. The company entered the Chinese pharmaceutical industry through the company's predecessor, Yichang Changjiang Pharmaceutical Co., Ltd., which was founded in 2001. Up to now, the company has a business history of more than 20 years, and its pharmaceutical sales performance and R&D capabilities rank among the leading positions in the domestic pharmaceutical industry. On May 11, 2015, the Company was restructured as a limited company and successfully listed on the main board of the Hong Kong Stock Exchange Limited (“Stock Exchange”) on December 29, 2015, stock code 01558. Since its establishment, the company has always adhered to the pharmaceutical concept of “serving the Chinese with higher standards”, and has a strong industrial base and leading competitive advantage in pharmaceutical manufacturing and marketing. As of June 30, 2023, the company has a nationwide product distribution network and 1,767 professional sales personnel in China. One of our core products, Colvir (oseltamivir phosphate), is a first-line drug for clinical application against influenza virus in China. Its granular dosage form is our exclusive patented product. Oseltamivir phosphate was included in the “National Essential Drugs Catalogue (2018 Edition)” in 2018. In 2019, our oseltamivir phosphate capsule dosage form was successfully approved and passed the generic drug quality and efficacy consistency evaluation (“consistency evaluation”), making it the first variety in China to meet this standard. In 2020, oseltamivir phosphate continued to be selected for the “Influenza Diagnosis and Treatment Plan (2020 Edition)” issued by the General Office of the National Health Commission. In 2022, our oseltamivir phosphate products continued to be selected in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2022 Edition)” issued by the Ministry of Human Resources and Social Security of China. In addition, the company has established strategic partnerships with many well-known pharmaceutical companies; reached a strategic partnership with Sinopharm Group Yi Pharmaceutical Co., Ltd. (Shenzhen Stock Exchange: 000028.SZ), and the first operation project was officially launched in 2018; a strategic cooperation framework agreement was signed with Kyushu Tong Pharmaceutical Group Co., Ltd. (“Kyushu Connect”). Based on this, the company authorized the relevant specifications of the product Kewei to Jiuzhou Tong's OTC (OTC) channel in mainland China for a period of three years; with the Wuhan Institute of Virology of the Chinese Academy of Sciences and the country The Emergency Prevention and Control Drug Engineering Technology Research Center and Guangdong Dongyangguang Pharmaceutical Co., Ltd. (previously known as Guangdong Dongyangguang Pharmaceutical Co., Ltd., “Guangdong Dongyangguang Pharmaceutical”) signed a letter of intent. Based on this, all parties will jointly establish a national civil-military integration collaborative industrialization platform for emergency prevention and control drugs and a national antiviral drug center. The company believes that the above strategic cooperation relationship will bring ideal development prospects to the company's business. The company has always adhered to the development strategy of specialization, branding and differentiation, and is committed to building the unique brand characteristics and core competitiveness of “Dongyang Changjiang Pharmaceutical” within the industry, creating more value for pharmaceutical consumers and partners. In the future, the company will further enrich its product line, develop markets, improve international production standards and quality of products, continue to expand marketing and sales coverage, promote further growth in the company's business and profitability, and seek higher economic benefits and benefits for investors.

Company Profile

Symbol01558
Company NameHEC CJ PHARM
ISINCNE1000023R6
Listing Date12/29/2015
Issue Price15.00
Shares Offered90.13M share
Founded08/08/2001
RegistrationChina
ChairmanXinfa Tang
SecretaryQiyun\huangweichao Peng
Audit InstitutionKPMG
Company CategoryOther
Registered Office38 Binjiang road, Yidu, Yichang, Hubei province, china
Head Office and Principal Place of Business40th Floor, Dah Sing Financial Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees4618
MarketHong Kong motherboard
Phone0769-81768886
Fax0769-81768866
Emailchangjiangpharm@dyg-hec.com
Business Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. is a Chinese company mainly engaged in pharmaceutical production and sales. Its business also includes research and development, marketing and distribution of pharmaceuticals. The company's products include antiviral drugs, endocrine and metabolic drugs, and cardiovascular drugs. Its core product portfolio includes “Corvie”, “Ertonshu”, “Oumeining”, “Xinhaining” and “Xining”.

Company Executives

  • Name
  • Position
  • Salary
  • Juncai Jiang
  • Remuneration Committee Member,Executive Director,GM
  • 1.27M
  • Danjin Wang
  • Deputy GM,Executive Director
  • 917.00K
  • Shuang Li
  • Deputy GM,Executive Director
  • 798.00K
  • Hao Chen
  • Executive Director
  • --
  • Xinfa Tang
  • Chairman,Audit Committee Member,Authorized Representative,Non-Executive Director
  • --
  • Jianxin Tang
  • Independent Non-Executive Director,Remuneration Committee Member,Audit Committee Chairman,Nomination Committee Member
  • 100.00K
  • Ling Xiang
  • Nomination Committee Member,Remuneration Committee Chairman,Independent Non-Executive Director,Audit Committee Member
  • 100.00K
  • Xuechen Li
  • Nomination Committee Chairman,Independent Non-Executive Director
  • 340.00K
  • Shengchao Wang
  • Quality Section Chief,Employee representative supervisor
  • 455.00K
  • Zhonghua Luo
  • Shareholders' representatives and supervisors
  • 827.00K
  • Jinlong Tang
  • Chairman of the Supervisory Board
  • 915.00K
  • Qiang Zhang
  • Finance Director
  • --
  • Qiyun Peng
  • Company Secretary,Joint Company Secretary
  • --
  • Weichao Huang
  • Authorized Representative,Joint Company Secretary
  • --
  • Yangui Chen
  • sales director
  • 1.03M

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg